The Why of YY1: Mechanisms of Transcriptional Regulation by Yin Yang 1 by Verheul, T.C.J. et al.
fcell-08-592164 September 28, 2020 Time: 13:55 # 1
MINI REVIEW
published: 30 September 2020
doi: 10.3389/fcell.2020.592164
Edited by:
Patrizio Dimitri,
Sapienza University of Rome, Italy
Reviewed by:
Benjamin Bonavida,
University of California, Los Angeles,
United States
Zong Wei,
Mayo Clinic Arizona, United States
*Correspondence:
Tahsin Stefan Barakat
t.barakat@erasmusmc.nl
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Epigenomics and Epigenetics,
a section of the journal
Frontiers in Cell and Developmental
Biology
Received: 06 August 2020
Accepted: 09 September 2020
Published: 30 September 2020
Citation:
Verheul TCJ, van Hijfte L,
Perenthaler E and Barakat TS (2020)
The Why of YY1: Mechanisms
of Transcriptional Regulation by Yin
Yang 1.
Front. Cell Dev. Biol. 8:592164.
doi: 10.3389/fcell.2020.592164
The Why of YY1: Mechanisms of
Transcriptional Regulation by Yin
Yang 1
Thijs C. J. Verheul1†, Levi van Hijfte2†, Elena Perenthaler3† and Tahsin Stefan Barakat3*
1 Department of Cell Biology, Erasmus MC University Medical Center, Rotterdam, Netherlands, 2 Department of Neurology,
Erasmus MC University Medical Center, Rotterdam, Netherlands, 3 Department of Clinical Genetics, Erasmus MC University
Medical Center, Rotterdam, Netherlands
First described in 1991, Yin Yang 1 (YY1) is a transcription factor that is ubiquitously
expressed throughout mammalian cells. It regulates both transcriptional activation and
repression, in a seemingly context-dependent manner. YY1 has a well-established role
in the development of the central nervous system, where it is involved in neurogenesis
and maintenance of homeostasis in the developing brain. In neurodevelopmental and
neurodegenerative disease, the crucial role of YY1 in cellular processes in the central
nervous system is further underscored. In this mini-review, we discuss the various
mechanisms leading to the transcriptional activating and repressing roles of YY1,
including its role as a traditional transcription factor, its interactions with cofactors and
chromatin modifiers, the role of YY1 in the non-coding genome and 3D chromatin
organization and the possible implications of the phase-separation mechanism on YY1
function. We provide examples on how these processes can be involved in normal
development and how alterations can lead to various diseases.
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INTRODUCTION
Yin Yang 1 (YY1) is a transcription factor (TF) that was first described in 1991 by three independent
groups, who all named the protein differently based on the molecular mechanisms they associated
it with. It was called NF-E1, as it binds the µE1 intron enhancer at the immunoglobulin heavy chain
(IgH) locus (Park and Atchison, 1991) or δ, as it binds the delta motif in the promoter of ribosomal
protein genes (Hariharan et al., 1991). The name Yin Yang 1 was eventually broadly adopted, as it
captures the dual activity of YY1 as both a transcriptional activator and repressor (Shi et al., 1991).
Similarly, the YY1 family member YY2 has this dual activity (Nguyen et al., 2004).
YY1 is ubiquitously expressed in mammalian cells. It forms homodimers that seem to be
stabilized by low specificity RNA binding (Wai et al., 2016). YY1 homodimers bind a relatively
small sequence motif (5′-CCGCCATNTT-3′), often found in enhancers and promoters, via the
four C2H2 zinc fingers in its C-terminal domain (Hyde-DeRuyscher et al., 1995; Yant et al., 1995;
Figure 1). YY1 and its paralog, YY2, share overall 56% homology at the aminoacid sequence,
reaching 86% of conservation in the zinc-fingers region. This high degree of homology might
result in YY2 binding to the same YY1 DNA binding motif (Nguyen et al., 2004). The DNA
binding zinc fingers partially overlap with sequences involved in transcriptional repression.
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FIGURE 1 | Schematic diagram of human YY1 domains. Human YY1 is composed of 414 amino acids. It binds a small DNA sequence (5′-CCGCCATNTT-3′)
through the four C2H2-type zinc fingers located at the C-terminal of the protein (amino acid 296–320, 325–347, 353–377, 383–407). The REPO domain (aa
201–226) and a glycine-lysine rich domain (GK-rich, aa 170–200) mediate transcriptional repression. The REPO domain is responsible for the interaction with
polycomb group proteins while the GK rich domain with histone deacetylases (HDAC). The N-terminal region of the protein mediates transcriptional activation. It is
composed mainly by acidic amino acids (aa 1–154) and by a stretch of 11 histidines (aa 70–80), that are thought to stimulate YY1 accumulation in nuclear speckles.
In blue, the reported causative variants of Gabriele-de Vries syndrome are indicated.
In the N-terminal region a transcriptional activator domain is
located (Shi et al., 1991). YY1 influences transcription by the
recruitment of cofactors (Gordon et al., 2006). For example,
the REPO domain interacts with polycomb group proteins, to
recruit repressive cofactors to specific genes (Wilkinson et al.,
2006, 2010). Cohesin and condensin, key factors of 3D chromatin
organization, also interact with the REPO domain of YY1 (Pan
et al., 2013). Another YY1 domain contains a his tract consisting
of eleven consecutive histidine residues, and is proposed to
stimulate YY1 accumulation in nuclear speckles (Salichs et al.,
2009), that play an important role in RNA metabolism (Galganski
et al., 2017). Interestingly, YY1 itself plays a role in pre-mRNA
splicing (Rambout et al., 2018). Binding intronic enhancer
motives allows YY1 to activate gene expression and promote
splicing (Bianchi et al., 2013).
YY1 is a crucial factor regulating cell proliferation and
apoptosis (Deng et al., 2010; Nicholson et al., 2011) and
it has been implicated in many regulatory mechanisms in
different tissues. In the brain, YY1 plays a well-established
role in neuronal development (Gabriele et al., 2017; Morales-
Rosado et al., 2018; Zurkirchen et al., 2019). In mice, a
homozygous Yy1 knock-out results in peri-implantation
lethality while heterozygous mutations cause growth retardation
and neurulation defects (Donohoe et al., 1999). In humans,
YY1 haploinsufficiency causes Gabriele-de Vries syndrome
(OMIM #617557) (Gabriele et al., 2017; Morales-Rosado
et al., 2018), characterized by psychomotor delay and
intellectual disability alongside many comorbidities, including
craniofacial dysmorphisms, intra-uterine growth restriction and
behavioral alterations.
Recent findings concerning YY1 activity in chromatin
rearrangement and its importance in neuronal development
have caused re-evaluation of YY1 function. This review focusses
on basic transcriptional mechanisms that YY1 has been
implicated in and considers its function in context of neuronal
development and disease.
MECHANISMS OF GENE ACTIVATION
AND SILENCING BY YY1
The Function of YY1 as a Traditional
DNA-Binding Transcription Factor
A key question in the YY1 field is how a DNA-binding TF can
act as both a transcriptional activator and repressor. Multiple
mechanisms have been suggested, including post-translational
modifications of YY1 (Yao et al., 2001) and co-factor dependency
(Gordon et al., 2006). Acetylation of the C-terminal domain
of YY1, for example, reduces DNA-binding capacity in vitro,
whereas acetylation of the central domain is required for YY1
to act as a full repressor (Yao et al., 2001). In mouse anterior
neuroectoderm development, the acetylation of YY1 is required
for Otx2 activation (Takasaki et al., 2007). Only acetylated YY1
binds an essential enhancer 5kb upstream of the homeobox
gene Otx2 to prompt its expression (Takasaki et al., 2007).
Post-translational modifications of YY1, thus, seem to influence
whether YY1 can activate or repress transcription.
Another explanation for YY1s context-dependent
transcriptional activation or repression is the interplay
between YY1 and its cofactors (Yao et al., 2001). Protein-
protein interactions exist between YY1 and DNA-binding
cofactors such as SpI (Seto et al., 1993) and c-Myc (Shrivastava
et al., 1993). Bound to DNA, YY1 tethers cofactors directly
to promoters, such as YY1 associated factor 1 (YY1AP), that
boosts transcription (Wang et al., 2004). YARP, a structural
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homolog of YY1AP, is expressed in brain, heart and placenta
tissue suggesting it acts as another co-activator of YY1 (Ohtomo
et al., 2007). Additionally, YY1 also recruits co-repressors to
the DNA, such as Smad family members repressing TGF-
β signaling and cell differentiation (Kurisaki et al., 2003).
In vitro, YY1 is able to bind promoter sequences and recruit
polymerase by interacting with general TFs. Overlapping DNA
binding sites of YY1 and transcriptional activators provide
another explanation for YY1-mediated repression. Since
DNA-binding of YY1 and an activator at a given locus can
be mutually exclusive, YY1 binding can block the activating
factor. For example, in mammary epithelial cells, YY1 represses
β-casein competing with the latent-state mammary gland
specific factor (MGF) of the STAT family, STAT5A (Raught
et al., 1994). Upon lactation, MGF is activated, increasing
its DNA-binding affinity and enabling it to replace YY1 and
de-repress β-casein (Shi et al., 1997). Independent of binding
the DNA, YY1 can regulate transcription by protein-protein
interactions with other regulators (Galvin and Shi, 1997). In
mouse neurons, Yy1 and its interacting partner Brd4 activate
Senp1, an upstream regulator of glutamate signaling, which plays
a pivotal role in neuronal plasticity (Wu and Donohoe, 2019).
Dephosphorylation of Yy1 upon membrane depolarization
depletes the Senp1 promoter of Yy1-Brd4, consequently
repressing Senp1 expression (Wu and Donohoe, 2019). This
example illustrates the mechanisms of both post-translational
YY1 modifications and co-factor dependency that partly explain
how a ubiquitously expressed TF can be an activator or repressor
depending on the cellular context.
The Interplay Between YY1 and
Chromatin Modifications
Among YY1 interactors, are multiple chromatin modifiers,
suggesting chromatin modifications might explain YY1
functioning as a transcriptional repressor or activator. YY1 can
direct the Polycomb complex to specific DNA loci, initiating
methylation of histone 3 lysine 27 (H3K27me3) (Atchison
et al., 2003; Wilkinson et al., 2006). Furthermore, YY1 interacts
with histone deacetylases (HDACs) associated with gene
silencing. Several members of this family, such as HDAC1,
HDAC2 and HDAC3, interact with YY1 both in vitro and
in vivo (Yang et al., 1997). Interestingly, YY1 also interacts
with histone acetyltransferases (HATs) like p300 (Lee et al.,
1995) and CREB binding protein (CBP), activating transcription
(Lee et al., 1995; Austen et al., 1997). Besides acetylating
or de-acetylating histones, HATs and HDACs modify YY1
itself, regulating its DNA-binding affinity and activity as a
transcriptional regulator (Yao et al., 2001). In addition to histone
3 modifications, YY1 promotes transcription by the recruitment
of the methyltransferase PRMT1, which methylates histone 4
arginine 3 (Rezai-Zadeh et al., 2003).
Moreover, YY1 has been shown to activate transcription
by interacting with chromatin remodeling complexes involved
in the shifting and repositioning of nucleosomes, such as
the INO80 complex (Cai et al., 2007; Wu et al., 2007) and,
more recently, the BAF complex (Wang et al., 2018). The
interaction with the INO80 complex is also thought to play
a role in facilitating the access of YY1 to its target genes
(Wu et al., 2007). Hence, through a plethora of molecular co-
factor interactions, YY1 influences chromatin modifications and
ultimately gene expression.
YY1 Regulates Transcription Through the
3D Chromatin Organization
At first glance, YY1 does not seem essential for 3D chromatin
organization, as the majority of its binding sites are close to
transcription start sites (TSSs) and only a minority is located
distal from regulated genes (Gabriele et al., 2017; Varum et al.,
2019; Zurkirchen et al., 2019). However, in YY1-haploinsufficient
lymphoblastoid cell lines, the most differentially expressed genes
were controlled by those distal YY1 binding sites (Gabriele et al.,
2017). Likewise, in T-helper cells, YY1 seems to mainly influence
gene expression through long-distance DNA interactions (Lee,
2014). Interactions between YY1 and proteins involved in
chromatin organization, such as CTCF and cohesin (Pan et al.,
2013; Schwalie et al., 2013), further implicate a role in 3D
chromatin organization.
Loop extrusion allows cohesin to actively form DNA loops
(Kim et al., 2019). CTCF, a DNA-binding protein, delimits
these DNA loops, demarcating isolated chromatin structures that
can be as large as 1 Megabase, called topologically associating
domains (TADs) (Zuin et al., 2014; Merkenschlager and Nora,
2016; Rao et al., 2017). Within TADs, long-distance DNA
interaction is facilitated between enhancers and promoters
by chromatin structuring proteins. CTCF itself is, however,
not crucial for the majority of enhancer-promoter interactions
(Phillips and Corces, 2009). Recently, YY1 was identified as
the structural factor that regulates the formation of DNA
loops within the larger CTCF-CTCF domains in a wide
variety of mammalian cell types, indicating that YY1-mediated
long-distance promoter-enhancer interactions are a general
mechanism in mammalian cells (Weintraub et al., 2017). Like
CTCF, YY1 forms homodimers and binds hypomethylated DNA
to facilitate long-distance DNA interactions. In contrast to CTCF,
however, YY1 binds to a consensus sequence mainly present
in enhancers and promoters and is only scarcely associates
with insulators (López-Perrote et al., 2014; Beagan et al., 2017;
Weintraub et al., 2017).
In neuronal differentiation specifically, TAD organization was
found to be less conserved between cell types and differentiation
stages than initially thought (Wang et al., 2012; Maurano et al.,
2015). These findings triggered research into the possible role of
dynamic chromatin organization during differentiation of neural
progenitor cells (NPCs) (Beagan et al., 2017). Surprisingly, YY1
appeared to instigate DNA loop formation and NPC-specific
promoter-enhancer interactions (Beagan et al., 2017). These YY1-
mediated DNA loop formations occur within CTCF-CTCF DNA
loops (Beagan et al., 2017). These findings introduce a new
identity of YY1 as a structural protein in addition to its role as
a traditional TF, providing an even broader understanding of the
multitude of cellular mechanisms that employ the ubiquitously
expressed YY1 protein to regulate transcription.
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YY1 IN HEALTH AND DISEASE
The Role of YY1 in Neurodevelopment
Several studies show that YY1 plays a role in neurodevelopmental
disorders (Donohoe et al., 1999; Varum et al., 2019; Zurkirchen
et al., 2019), but the mechanisms behind this are still
incompletely understood. In mouse embryos, YY1 has
proven essential for neurodevelopment (Varum et al., 2019;
Zurkirchen et al., 2019; Dong and Kwan, 2020). In murine
models, Yy1 conditional knock-out (cKO) induced at an
early stage of cortical development, caused an increased
apoptosis rate and cell cycle arrest in neuroepithelium and
NPCs (Zurkirchen et al., 2019; Dong and Kwan, 2020). This
effect on NPCs however decreased markedly when cKO was
induced at later stages (Zurkirchen et al., 2019). Accordingly,
another study by Varum and colleagues showed that Yy1
cKO in mice affects neural crest (NC) development in a
strict stage dependent manner. Early KO caused a reduction
of multiple NC-derived lineages, whereas late KO (after
embryonic day 11.5) resulted in no clear phenotypic difference
compared to control (Varum et al., 2019), showing a decreased
dependency on YY1 regulated processes at later stages of
neuronal development.
Surprisingly, early and late Yy1 cKO, caused similar changes in
gene expression, which indicates that the decreased importance
of YY1 during neuronal development does not coincide
with a shift in YY1 target genes (Zurkirchen et al., 2019).
As YY1-regulated genes seemed to be mainly implicated in
metabolic pathways and protein translation, influencing the
cell cycle machinery indirectly in NPCs and NC (Varum
et al., 2019; Zurkirchen et al., 2019), Zurkirchen and colleagues
hypothesized that a decreasing dependency on YY1 during
cortical development is due to a decreased biosynthetic demand
and decreased proliferation rate of cells at later stages of
corticogenesis, making these cells less vulnerable to defects
in these pathways.
The importance of YY1 in early development is also attributed
to apoptosis inhibition (Sui et al., 2004; Chen et al., 2018;
Zurkirchen et al., 2019; Dong and Kwan, 2020). In mice, cKO
of Yy1 at an early embryonic stage caused an accumulation
of p53 protein and increased apoptosis (Zurkirchen et al.,
2019; Dong and Kwan, 2020). This effect could be partially
reversed in Yy1/Trp53 double cKO mice, indicating that YY1
is important in the downregulation of p53, an important
apoptosis regulator, to facilitate NPC survival (Zurkirchen
et al., 2019). Additionally, YY1 inhibits apoptosis by regulation
of the Planar cell polarity effector gene FUZ, an important
apoptosis factor in neuronal development. Alterations of
FUZ/Fuz expression cause neural tube defects in humans and
are associated with an increased number and disorganization
of NC cells in mice (Gray et al., 2009; Tabler et al., 2013;
Seo et al., 2015). YY1 can induce hypermethylation of the
FUZ promoter, resulting in FUZ downregulation and inhibition
of its apoptotic signal (Chen et al., 2018). A reduction in
soluble YY1 protein reverses this hypermethylation at the
FUZ promoter and is associated with increased apoptosis
(Chen et al., 2018).
Recently, YY1 was also linked to NPC differentiation by
downregulation of Sox2 expression in mice (Knauss et al., 2018).
SOX2 is a known pluripotency factor and is also involved in
the maintenance of the undifferentiated state of NPCs (Graham
et al., 2003). YY1 was implicated in Sox2 downregulation in
mouse brain cortexes during neuronal development by binding
the Sox2 locus and physically halting transcription. These results
accentuate a pro-differentiation role for YY1 (Knauss et al., 2018)
that contradicts previously described work, which shows that
YY1 is vital for NPCs maintenance and proliferation in early
development (Varum et al., 2019; Zurkirchen et al., 2019).
Given its complex function, it is not surprising that the role of
YY1 in neurodevelopment remains a topic of active discussion.
It remains important to also consider YY1 function in a context
dependent manner (He and Casaccia-Bonnefil, 2008). Indeed,
YY1 has been shown to exert context dependent functions in
several cell types, like B-cells and heart muscle (Liu et al., 2007;
Beketaev et al., 2015). For neurodevelopment specifically, context
dependent YY1 functionality is still incompletely understood and
will be an interesting topic to further explore in future studies.
The Role of YY1 in Disease
In humans, YY1 haploinsufficiency causes Gabriele−de Vries
Syndrome, which is characterized by cognitive impairment,
behavioral alterations, intrauterine growth restriction,
feeding problems and sometimes congenital malformations
(Gabriele et al., 2017; Morales-Rosado et al., 2018). One
of the consequences of YY1 haploinsufficiency in humans
is a loss of H3K27 acetylation at enhancers bound by YY1
(Gabriele et al., 2017). H3K27 acetylation is tightly associated
with active promoters and distal enhancers which indicates
that downregulation of YY1 affects chromatin regulation and
gene transcription (Hebbes et al., 1988; Gabriele et al., 2017).
Additionally, mutations in YY1 binding sites in specific non-
coding regulatory regions cause neurodevelopmental disorders
with a milder phenotype, since the effect of such mutations
is limited to the expression of the gene associated with this
regulatory region (Gabriele et al., 2018). For example, a disrupted
YY1-binding site in a brain-specific enhancer of ADGRL3 creates
a predisposition to attention-deficit/hyperactivity disorder
(ADHD) (Martinez et al., 2016).
Throughout life, YY1 regulates various neuroprotective
pathways, playing a central role in ischemic damage, Parkinson’s
and Alzheimer’s disease. For example, YY1 activates NRF2,
which in turn initiates an antioxidant response to protect
brain cells against ischemic damage following cerebrovascular
accidents (Liu et al., 2018). In Parkinson’s Disease, YY1 is
downregulated in microglia, along with other neuroprotective
pathways like mTOR and TGF-β (Pal et al., 2016). YY1 regulates
the expression of NRF2-mediated anti-oxidant response and
the transmembrane transporter SVCT2-dependent import of the
protective drug ascorbate (Qiao and May, 2012; Gureev and
Popov, 2019), which are key targets for Parkinson’s disease
treatment developments. A bioinformatics approach to uncover
regulators of Alzheimer’s Disease appointed YY1 as one of
the master regulators (Aubry et al., 2015). Interestingly, in
contrast to Parkinson’s, in Alzheimer disease higher levels of
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YY1 mRNA were detected in human autopsy-derived whole
brain samples and isolated neuron samples compared to controls
(Aubry et al., 2015). It would be tempting to speculate that
the protective function requires tightly regulated levels of YY1,
while aberrant levels contribute to the onset and progression of
neurodegenerative diseases.
Analogous to its role in healthy state, YY1 has a highly
context-dependent function also in cancer (Khachigian, 2018;
Sarvagalla et al., 2019). YY1 can act as a tumor suppressor
or stimulator (Khachigian, 2018). For example, YY1 inhibits
proliferation in pancreatic cancer through downregulation of
SOX2 (Zhang et al., 2017), while in melanoma, YY1 promotes
tumor growth, and YY1 cKO prevents tumorigenesis in a
melanoma murine model (Varum et al., 2019). Interestingly,
both early NC development and melanoma tumorigenesis
seem to be particularly sensitive to alterations in the same
metabolic processes that are regulated by YY1 (Varum et al.,
2019). Of note, next to YY1, YY2 can also be upregulated
in cancer cells (Kaufhold et al., 2017). Possibly, due to
the high degree of homology, some YY1 antibodies might
FIGURE 2 | Mechanism of transcriptional activation or repression by YY1. (A) YY1 can act as a traditional DNA-binding transcription factor interacting with an
extensive list of co-factors that mediate the activation or repression of transcription. Some are listed in the figure. (B) YY1 can interact with chromatin remodeling
complexes that regulate transcription by regulating chromatin accessibility. (C) YY1 regulates transcription via the formation of enhancer-promoter loops within larger
TADs. The red ring represents Cohesin. (D) The phase separation model might also explain the activity of YY1 as a dynamic activator or repressor of transcription,
based on the cocktail of co-factors present in the highly concentrated phase-separated droplets.
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not discriminate between the two paralogs, which can be
relevant for the interpretation of studies which only employ
immunohistochemistry (Kaufhold et al., 2017).
In gliomas, YY1 is overexpressed and contributes to tumor
progression (Baritaki et al., 2009). YY1 has been implicated
in glioma tumor cell proliferation due to its inhibitory effect
on p53 protein levels (Gao et al., 2018). In glioma cell lines,
YY1 has been shown to be regulated by the MicroRNA miR-
218 (Gao et al., 2018). Normally, miR-218 is downregulated in
glioma (Jun et al., 2015). When miR-218 is overexpressed, YY1 is
downregulated and the inhibition of the tumor suppressor p53
is nullified (Gao et al., 2018). Additionally, YY1 was shown to
upregulate transcription of the long non-coding RNA SNHG17,
which activates the Wnt/β-catenin signaling pathway and thus
contributes to the proliferation of glioma cells and inhibition of
apoptosis (Li et al., 2020).
Proteomics identified YY1 as a regulatory factor involved in
cancer stem cell (CSC) maintenance across 17 different cancer
types (Kaufhold et al., 2016). YY1 expression was associated with
that of CSC regulators SOX2, BMI1, and OCT4. In glioma stem
cells (GSCs) Notch signaling was shown to direct YY1 to repress
gene transcription involved in cell differentiation by causing
locus specific methylation of histone H3K27 (Katsushima et al.,
2016). Notch signaling is known to inhibit differentiation and its
regulatory mechanisms seem to be vital in neuronal development
as well as in GSC maintenance (Bazzoni and Bentivegna,
2019). Together, the ability of YY1 to inhibit apoptosis and its
association with CSC maintenance could indicate a broader role
for YY1 in tumor biology.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
YY1 activates or represses genes depending on the cellular
context. These seemingly contradictory functions led to the
name Yin Yang 1 and sparked investigations into YY1 on
a mechanistic level. Here, we briefly discussed the roles that
YY1 plays at different levels of transcriptional regulation.
First, as a (traditional) DNA-binding TF, YY1 interacts with
an extensive list of general and context-dependent cofactors.
Recruitment of these cofactors by YY1 is important for
direct repression or activation of genes and was shown to
play a role in pre-mRNA splicing. Second, YY1 interacts
with chromatin remodeling complexes to regulate transcription
through chromatin accessibility. Third, by controlling chromatin
looping, YY1 can enable and stabilize enhancer-promoter
interactions to activate expression (Figure 2).
For the human brain, YY1 is essential for proper development,
maintenance, and protection from degeneration. It remains
difficult to speculate which of the described roles of YY1 is most
important in the brain. As a structural factor, YY1 was shown
to facilitate NPC-specific long-distance promoter-enhancer DNA
interactions (Beagan et al., 2017). A developmental stage-specific
dependency on YY1 in neuronal development, stresses YY1s role
in metabolic pathways and protein translation (Varum et al.,
2019; Zurkirchen et al., 2019). Further research is needed to
elucidate the interplay between YY1 as a regulator of chromatin
looping and its role as a traditional TF. Another topic for
further research would be the RNA-binding capability of YY1 in
relation to transcriptional regulation, as it was shown that RNA
binding stabilizes YY1 homodimers and that, compared to DNA
binding, the RNA binding occurs with low sequence specificity
(Sigova et al., 2015; Wai et al., 2016). In light of the extensive
list of YY1 cofactors, it is important to consider the recently
proposed phase-separation mechanism, where DNA bound TFs
drive the formation of droplets with high concentrations of
other TFs and cofactors necessary for transcription (Hahn, 2018;
Figure 2D). For example, the TFs OCT4 and GCN4 can form
such phase-separated droplets with a high concentration of many
cofactors upon enhancer binding (Boija et al., 2018). The high
concentration of factors in phase-separated droplets would allow
rapid interactions of many factors that during in vitro assays
would seem too weak (Hahn, 2018). In highly concentrated
phase-separated droplets YY1 might be able to interact with even
more cofactors than those that have been identified in in vitro
assays. The ambivalence of YY1 being a repressing and activating
TF fits the proposition of the studies on phase-separation that
transcriptional regulation is a dynamic biochemical equilibrium
(Silveira and Bilodeau, 2018).
Being a ubiquitously expressed transcriptional regulator,
it comes as no surprise that YY1 plays a role in multiple
regulatory pathways that work in concert to execute the correct
transcriptional program in different cell types and at different
stages of development. Reviewing the body of literature on
YY1, the dualistic reference in its name still fits well. The
mechanisms behind seemingly opposite forces of repression
and activation are complementary and interconnected. The
molecular mechanisms of YY1 also teach us about transcriptional
regulation in general. Similar to YY1, other TFs might depend
on the cellular context to play different roles with different
transcriptional outcomes. GATA1 and co-factor FOG1 for
example, activate or repress their target genes in a context-
depended manner (Welch et al., 2004), which is mediated by
the Nucleosome Remodeling and Deacetylase (NuRD) complex
(Miccio et al., 2010). Further research into the different roles
of YY1 is warranted. In addition to answering fundamental
questions on transcriptional regulation, future studies on YY1
could have clinical implications for neurodevelopmental and
neurodegenerative disorders as well as cancer.
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